SCHEMBL29488123

SCHEMBL29488123

Cc1cnc(N)nc1-c1c[nH]c2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 8/20 0.71
▸ CDK5 Q00535 7/20 0.71
▸ CDK5R1 Q15078 7/20 0.71
▸ MAP3K14 Q99558 2/20 0.68
▸ GSK3B P49841 1/20 0.56
▸ DYRK1A Q13627 1/20 0.56
▸ JAK2 O60674 1/20 0.55
▸ JAK1 P23458 1/20 0.55
▸ CCNT1 O60563 1/20 0.52
▸ CCNK O75909 1/20 0.52
▸ CDK7 P50613 1/20 0.52
▸ CDK9 P50750 1/20 0.52
▸ CCNH P51946 1/20 0.52
▸ MNAT1 P51948 1/20 0.52
▸ CDK12 Q9NYV4 1/20 0.52
▸ DHFR P00374 1/20 0.51
▸ PIM1 P11309 1/20 0.50
▸ ATP4A P20648 1/20 0.47
▸ ATP4B P51164 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16075920 1.00 CLK1 (0.71) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL29488129 0.83 MAP3K14 (0.65) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL24839575 0.83 CLK1 (0.71) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL20691183 0.83 CLK1 (0.71) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL17150733 0.83 CDK5 (0.71) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL517438 0.83 JAK2 (0.55) CLK1CDK5CDK5R1MAP3K14JAK2
SCHEMBL30108168 0.83 JAK2 (0.55) CLK1CDK5CDK5R1MAP3K14JAK2
SCHEMBL12627364 0.81 JAK2 (0.65) CLK1CDK5CDK5R1MAP3K14JAK2
SCHEMBL21026876 0.80 CDK5 (0.69) CLK1CDK5CDK5R1MAP3K14GSK3B
SCHEMBL24839810 0.80 CLK1 (0.66) CLK1CDK5CDK5R1MAP3K14GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents HANMI PHARM. CO., LTD. (KR) 2025-07-08 — — US claimed
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS HANMI PHARM. CO., LTD. (KR) 2022-11-10 — — US claimed
US-11292786-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO., LTD. (KR) 2022-04-05 — — US claimed
US-20260092051-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME HANMI PHARMACEUTICAL CO LTD (KR) 2026-04-02 — — US disclosed
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents HANMI PHARM. CO., LTD. (KR) 2025-07-08 — — US disclosed
US-12325698-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO., LTD. (KR) 2025-06-10 — — US disclosed
US-20230002358-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME HANMI PHARM. CO., LTD. (KR) 2023-01-05 — — US disclosed
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS HANMI PHARM. CO., LTD. (KR) 2022-11-10 — — US disclosed
US-11292786-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO., LTD. (KR) 2022-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002358-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME DPYD, TYMS, TYMP CLK1 3577/4885CDK5 438/4885CDK5R1 675/4885
US-12325698-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same DPYD, TYMS, TYMP CLK1 3577/4885CDK5 438/4885CDK5R1 675/4885
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS FLT3, MCL1, CSF3R CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents FLT3, MCL1, CSF3R CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885
US-11292786-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same DPYD, TYMS, TYMP CLK1 3577/4885CDK5 438/4885CDK5R1 675/4885
US-20260092051-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME FLT3, FLT1, ADK CLK1 96/4885CDK5 715/4885CDK5R1 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback